Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Olfactory Function in Patients With Sinonasal Diseases: A Multicenter Observational Study

10 de noviembre de 2026 actualizado por: Gustavo Subtil Magalhães Freire, University of Brasilia

Olfactory Profile of Patients With Sinonasal Diseases: A Multicenter Cross-Sectional Observational Study in Brazil

This multicenter, cross-sectional observational study aims to characterize olfactory function in patients with sinonasal diseases and investigate its associations with disease severity, clinical characteristics, and inflammatory markers. Olfactory function will be assessed using the MultiScent-20 digital odor identification test. Additional assessments will include sinonasal symptom severity, quality of life, endoscopic and radiological findings, and clinical and laboratory markers suggestive of type 2 inflammation. Healthy volunteers without olfactory complaints will serve as a comparison group. The study is expected to enroll 3,800 participants across participating centers in Brazil.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Descripción detallada

This is a multicenter, cross-sectional observational study conducted in Brazilian outpatient otolaryngology settings. The study aims to investigate olfactory function in patients with chronic rhinosinusitis and other sinonasal diseases and to explore its associations with clinical manifestations, disease severity, and inflammatory characteristics.

Olfactory function will be objectively assessed using the MultiScent-20 digital odor identification test, which provides a score ranging from 0 to 20, with higher scores indicating better olfactory performance. Participants will undergo a single study assessment.

Clinical data will include sinonasal symptoms, SNOT-22 scores, visual analog scale ratings, nasal polyp scores, previous sinonasal surgeries, relevant comorbidities, and alcohol intolerance. Laboratory, histopathological, and imaging findings obtained during routine clinical care within the predefined eligibility window will be collected when available.

Criteria suggestive of type 2 inflammation will be evaluated using predefined clinical and laboratory characteristics. Missing clinical or laboratory information will not constitute an exclusion criterion. Analyses involving individual variables will include participants with the corresponding available data, whereas the total count of type 2 inflammatory criteria will be calculated only when all eight criteria have been assessed.

A comparison group of healthy volunteers without olfactory complaints will also be included. No therapeutic intervention will be administered as part of this observational study.

Tipo de estudio

De observación

Inscripción (Estimado)

3800

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasil
        • Reclutamiento
        • Hospital Universitário Professor Edgard Santos (HUPES)
    • Federal District
      • Brasília, Federal District, Brasil
        • Reclutamiento
        • Hospital Universitário de Brasília (HUB)
    • Goiás
      • Goiânia, Goiás, Brasil
        • Reclutamiento
        • Hospital das Clínicas da UFG
    • Paraná
      • Curitiba, Paraná, Brasil
        • Reclutamiento
        • Hospital IPO - sede Água Verde
    • Pernambuco
      • Recife, Pernambuco, Brasil
        • Reclutamiento
        • Hospital das Clínicas da UFPE
    • Piauí
      • Teresina, Piauí, Brasil
        • Reclutamiento
        • Hospital Getúlio Vargas (HGV)
    • Rio Grande do Sul
      • Canoas, Rio Grande do Sul, Brasil
        • Reclutamiento
        • Hospital Universitário Canoas
      • Porto Alegre, Rio Grande do Sul, Brasil
        • Reclutamiento
        • Hospital de Clínicas de Porto Alegre (HCPA)
    • Rio de Janeiro
      • Rio de Janeiro, Rio de Janeiro, Brasil
        • Reclutamiento
        • Hospital Universitário Pedro Ernesto
    • São Paulo
      • Ribeirão Preto, São Paulo, Brasil
        • Reclutamiento
        • Hospital das Clínicas da FMRP-USP - Campus
      • São Paulo, São Paulo, Brasil
        • Reclutamiento
        • Hospital das Clínicas da FMUSP
      • São Paulo, São Paulo, Brasil
        • Reclutamiento
        • Hospital São Paulo - Hospital Universitário da UNIFESP

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Adults aged 18 years or older with chronic rhinosinusitis or other sinonasal diseases and healthy volunteers without olfactory complaints, recruited at participating outpatient centers in Brazil.

Descripción

Inclusion Criteria:

Adults aged 18 years or older. Patients with chronic rhinosinusitis or other sinonasal diseases, or healthy volunteers without olfactory complaints participating in the comparison group.

Ability to understand and complete the study assessments.

Exclusion Criteria:

Illiteracy. Respiratory tract infection within the preceding seven days. Sinonasal surgery within the preceding six months. History of severe head trauma. Diagnosis of a neurodegenerative disease.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: OTHER
  • Perspectivas temporales: CROSS_SECTIONAL

Cohortes e Intervenciones

Grupo / Cohorte
Sinonasal Disease Participants

Adults with chronic rhinosinusitis or other sinonasal diseases.

Healthy Comparison Participants

Healthy adults without olfactory complaints.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
MultiScent-20 odor identification score
Periodo de tiempo: Once at enrollment (cross-sectional assessment).

Total number of correctly identified odors on the 20-item MultiScent-20 digital odor identification test. Scores range from 0 to 20; higher scores indicate better odor identification performance.

Once at enrollment (cross-sectional assessment).

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Sinonasal Outcome Test-22 (SNOT-22) total score
Periodo de tiempo: Once at enrollment (cross-sectional assessment).

Patient-reported sinonasal symptom burden assessed using the 22-item SNOT-22 questionnaire. Total scores range from 0 to 110; higher scores indicate greater symptom burden.

Once at enrollment (cross-sectional assessment).
Severity of four sinonasal symptoms on visual analog scales
Periodo de tiempo: Once at enrollment (cross-sectional assessment).

Severity will be assessed separately for nasal obstruction, rhinorrhea, facial pain or pressure, and olfactory dysfunction using four individual visual analog scales (VAS). Each score ranges from 0 (no symptoms) to 10 (maximum symptom intensity). Each symptom score will be analyzed in relation to the MultiScent-20 odor identification score. No combined VAS total score is prespecified.

Once at enrollment (cross-sectional assessment).
Nasal Polyp Score (NPS)
Periodo de tiempo: At enrollment, using available routine clinical assessment.

Endoscopic nasal polyp burden assessed using the Nasal Polyp Score, ranging from 0 to 8; higher scores indicate greater polyp burden. Applicable to participants with available endoscopic assessment.

At enrollment, using available routine clinical assessment.
Lund-Mackay computed tomography score
Periodo de tiempo: At enrollment; CT performed within the 12 months preceding enrollment, if available.

Extent of sinonasal opacification on computed tomography evaluated using the Lund-Mackay scoring system (total score 0-24; higher scores indicate more extensive radiologic disease). Assessed when routine-care imaging is available.

At enrollment; CT performed within the 12 months preceding enrollment, if available.
Peripheral blood eosinophil count
Periodo de tiempo: At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.

Absolute peripheral blood eosinophil count obtained from available routine-care laboratory testing.

At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.
Total serum immunoglobulin E (IgE)
Periodo de tiempo: At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.

Total serum IgE concentration obtained from available routine-care laboratory testing.

At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.
Number of clinical and laboratory criteria suggestive of type 2 inflammation in chronic rhinosinusitis
Periodo de tiempo: Once at enrollment, using clinical data and available routine-care tests obtained within the preceding 12 months when applicable.

Count of predefined clinical and laboratory criteria suggestive of type 2 inflammation in chronic rhinosinusitis, according to the guideline for use of biologics in chronic rhinosinusitis with nasal polyps cited in the study protocol. Clinical criteria: symptom onset between ages 30 and 50 years; marked improvement in olfaction following oral corticosteroid use; adult-onset asthma; aspirin or nonsteroidal anti-inflammatory drug intolerance; and bilateral nasal polyps associated with thick allergic- or eosinophilic-appearing nasal mucus, preferably confirmed by nasal endoscopy. Biomarker criteria: tissue eosinophils ≥10 cells/high-power field; blood eosinophils ≥250 cells/µL; or total serum IgE ≥100 IU/mL. The total number of criteria suggestive of type 2 inflammation will be calculated only for participants with complete data on all eight clinical and laboratory criteria. The count ranges from 0 to 8 and equals the number of positive criteria.

Once at enrollment, using clinical data and available routine-care tests obtained within the preceding 12 months when applicable.
Presence of selected comorbidities
Periodo de tiempo: Once at enrollment (cross-sectional assessment).

Presence or absence of relevant comorbidities, including asthma and aspirin-exacerbated respiratory disease (AERD), recorded from clinical history.

Once at enrollment (cross-sectional assessment).
Number of previous sinonasal surgeries
Periodo de tiempo: Once at enrollment (cross-sectional assessment).

The number of previous sinonasal surgeries will be recorded for each participant.

Once at enrollment (cross-sectional assessment).
Alcohol intolerance
Periodo de tiempo: Once at enrollment (cross-sectional assessment).

Alcohol intolerance will be assessed as a binary variable (yes/no), based on self-reported nasal symptoms following the consumption of alcoholic beverages.

Once at enrollment (cross-sectional assessment).

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Gustavo Subtil M. Freire, University of Brasilia

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de marzo de 2025

Finalización primaria (Estimado)

1 de noviembre de 2027

Finalización del estudio (Estimado)

1 de noviembre de 2027

Fechas de registro del estudio

Enviado por primera vez

10 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • UNB-OLFATO-RSC-2026
  • 68687423.5.0000.5558 (Otro identificador: Brazilian Research Ethics CAAE)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .